ReviewApplied microbiology and biotechnology2019
Perspectives of inclusion bodies for bio-based products: curse or blessing?
Review in Applied microbiology and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Potential of inclusion bodies for disease control in aquaculture and livestock.Veterinary and animal science · 2026Review
- Lysis and IB washing procedures significantly impact the recovery of rHumanized ranibizumab from inclusion bodies expressed in Escherichia coli.Bioprocess and biosystems engineering · 2026Article
- The Missing Link: Connecting Cultivation Conditions and Refolding Performance via Inclusion Body Biophysical Properties.Biotechnology and bioengineering · 2025Article
- Immobilized inclusion bodies of recombinant cold-adaptive lipase from Antarctic Pseudomonas sp. as catalysts.Applied microbiology and biotechnology · 2025Article
- Active Inclusion Bodies in the Multienzymatic Synthesis of UDP-N-acetylglucosamine.International journal of molecular sciences · 2025Article
- Expression, Sarkosyl Solubilization, DNase Activity, Purification, and SPR Binding Affinity of Recombinant Diphtheria Toxoid (rCRM197EK) Expressed in Escherichia coli BL21(DE3).Molecular biotechnology · 2025Article
- Magnetizing Biotech-Advances in (In Vivo) Magnetic Enzyme Immobilization.Engineering in life sciences · 2025Review
- Building Up Functional Coiled-Coil-Based Supramolecular Assemblies for Biomedical and Biotechnological Applications.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Development of high-performance inducible and secretory expression vector and host system for enhanced recombinant protein production.Scientific reports · 2024Article
- Bi-directionalized promoter systems allow methanol-free production of hard-to-express peroxygenases with Komagataella Phaffii.Microbial cell factories · 2024Article
- Immunomodulation Evidence of Nanostructured Recombinant Proteins in Salmonid Cells.Animals : an open access journal from MDPI · 2024Article
- Recombinant expression and characterization of Canine circovirus capsid protein for diagnosis.Frontiers in veterinary science · 2024Article
- Oligomerization and Adjuvant Activity of Peptides Derived from the VirB4-like ATPase ofBiomolecules · 2023Article
- Recombinant human TIM-3 ectodomain expressed in bacteria and recovered from inclusion bodies as a stable and active molecule.Frontiers in bioengineering and biotechnology · 2023Article
- Recombinant Globular Domain of TcpA Pilin fromLife (Basel, Switzerland) · 2022Article
- Recombinant cellobiohydrolase of Myceliophthora thermophila: characterization and applicability in cellulose saccharification.AMB Express · 2021Article
- At-Line Reversed Phase Liquid Chromatography for In-Process Monitoring of Inclusion Body Solubilization.Bioengineering (Basel, Switzerland) · 2021Article
- Expression and Purification of a Recombinant Enterotoxin Protein Using Different E. coli Host Strains and Expression Vectors.The protein journal · 2021Article
- Optimizing the Preparation Procedure of Recombinant PSCA, as a Practical Biomarker in Prostate Cancer.Iranian journal of biotechnology · 2021Article
- Title: insoluble proteins catch heterologous soluble proteins into inclusion bodies by intermolecular interaction of aggregating peptides.Microbial cell factories · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bacterium Escherichia coli is a major host for recombinant protein production of non-glycosylated products. Depending on the expression strategy, the recombinant protein can be located intracellularly, which often leads to protein aggregates inside of the cytoplasm, forming so the called inclusion bodies (IBs). When compared to other protein expression strategies, inclusion body formation allows high product titers and also the possibility of expressing proteins being toxic for the host. In the past years, the comprehension of inclusion bodies being only inactive protein aggregates changed, and the new term of non-classical inclusion bodies emerged. These inclusion bodies are believed to contain a reasonable amount of active protein within their structure. However, subsequent downstream processing, such as homogenisation of cells, centrifugation or solubilisation of IBs, is prone to variable process performance and is often known to result in low extraction yields. It is hypothesised that variations in IB quality attributes are responsible for those effects and that such attributes can be controlled by upstream process conditions. In this review, we address the impact of process design (process parameters) in the upstream on defined inclusion body quality attributes. The following topics are therefore addressed: (i) an overview of the range of inclusion body applications (including emerging technologies); (ii) analytical methods to determine quality attributes; and (iii) screws in process engineering to achieve the desired quality attributes for different inclusion body-based applications. Process parameters in the upstream can be used to trigger different quality attributes including protein activity, but are not exploited to a satisfying content yet. Design by quality approaches in the upstream are already considered for a multitude of existing processes. Further intensifying this approach may pave the industrial application for new IB-based products and improves IB processing, as discussed within this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.